Core Needle Biopsies as an Alternative Source for Ex Vivo Expanded TIL for Adoptive Cell Therapy in Triple-Negative Breast Cancer

被引:1
|
作者
Coman, Magdalena M. [1 ]
Pusztai, Lajos [2 ]
Hooley, Regina [3 ]
Andreveja, Liva [3 ]
Kim, Leah [1 ]
Joshi, Nikhil [4 ]
Bersenev, Alexey [5 ]
Krause, Diane [5 ]
Park, Tristen S. [1 ,6 ]
机构
[1] Yale Univ, Yale Sch Med, Dept Surg, New Haven, CT USA
[2] Yale Univ, Yale Canc Ctr, Dept Med, New Haven, CT USA
[3] Yale Univ, Yale Sch Med, Dept Radiol & Biomed Imaging, New Haven, CT USA
[4] Yale Univ, Yale Canc Ctr, Sch Med, Dept Immunobiol, New Haven, CT USA
[5] Yale Sch Med, Dept Lab Med & Pathol, New Haven, CT USA
[6] Yale Med Sch, New Haven, CT 06510 USA
关键词
breast cancer; adoptive cell therapy; TILs; TNBC; tumor-infiltrating lymphocytes;
D O I
10.1097/CJI.0000000000000495
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Adoptive transfer of ex vivo expanded tumor-infiltrating lymphocytes (TILs) have produced long-term response in metastatic cancers. TILs have traditionally been expanded from surgically resected specimens. Ultrasound-guided core needle biopsy (CNB) is an alternative method that avoids the morbidity of surgery and have added benefits which may include patients not amenable to surgery as well as the potential to produce TILs from multiple lesions in the same patient. We assessed the ability to produce and expand TILs from primary triple-negative breast cancer tumors from CNB (n=7) and demonstrate comparable expansion, phenotype and cytokine secretion after phorbol myristate acetate-ionomycin stimulation to TILs expanded from surgery (n=6). T cell Receptor clonality and diversity were also comparable between the two cohorts throughout the TIL culture. CNB is a safe and feasible method to obtain tumor tissue for TIL generation in patients with triple-negative breast cancer.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 50 条
  • [41] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
    Heeke, Arielle L.
    Tan, Antoinette R.
    CANCER AND METASTASIS REVIEWS, 2021, 40 (02) : 537 - 547
  • [42] Modified porphyrins for photodynamic therapy of triple-negative breast cancer
    Dial, Trinity
    Bradshaw, Joseph E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [43] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
    Arielle L. Heeke
    Antoinette R. Tan
    Cancer and Metastasis Reviews, 2021, 40 : 537 - 547
  • [44] Triple-negative breast cancer: molecular subtypes and targeted therapy
    Hirshfield, Kim M.
    Ganesan, Shridar
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2014, 26 (01) : 34 - 40
  • [45] Development of novel combination therapy for triple-negative breast cancer
    Lee, H.
    Lee, K.
    Lee, J.
    Yoon, K.
    Mohammad, A. M.
    Park, H. S.
    Park, J. S.
    Lee, S. -T.
    Sohn, J.
    BREAST, 2019, 44 : S36 - S37
  • [47] Modified porphyrins for photodynamic therapy of triple-negative breast cancer
    Neeley, Taylor
    Bradshaw, Jospeh E.
    Hayes, Timothy E.
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [48] Anti-androgen therapy in triple-negative breast cancer
    Barton, Valerie N.
    Gordon, Michael A.
    Richer, Jennifer K.
    Elias, Anthony
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2016, 8 (04) : 305 - 308
  • [49] A review of current progress in triple-negative breast cancer therapy
    Shen, Meiying
    Pan, Huawen
    Chen, Yuxia
    Xu, Yu Hang
    Yang, Weixiong
    Wu, Zhaojun
    OPEN MEDICINE, 2020, 15 (01): : 1143 - 1149
  • [50] Etiological roles of core promoter variation in triple-negative breast cancer
    Huang, Teng
    Li, Jiaheng
    Wang, San Ming
    GENES & DISEASES, 2023, 10 (01) : 228 - 238